<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huynh-Le MP</submitter><funding>NIBIB NIH HHS</funding><funding>Cancer Research UK</funding><funding>National Institute for Health Research (NIHR)</funding><funding>NCI NIH HHS</funding><pagination>755-761</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9372232</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.&lt;h4>Methods&lt;/h4>In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-th</pubmed_abstract><journal>Prostate cancer and prostatic diseases</journal><pubmed_title>Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.</pubmed_title><pmcid>PMC9372232</pmcid><funding_grant_id>NIHR201620</funding_grant_id><funding_grant_id>K08 EB026503</funding_grant_id><funding_grant_id>UG1 CA189974</funding_grant_id><funding_grant_id>29017</funding_grant_id><funding_grant_id>UM1 CA182883</funding_grant_id><funding_grant_id>18504</funding_grant_id><pubmed_authors>Gamulin M</pubmed_authors><pubmed_authors>Abraham A</pubmed_authors><pubmed_authors>APCB (Australian Prostate Cancer BioResource)</pubmed_authors><pubmed_authors>Huff CD</pubmed_authors><pubmed_authors>Berndt SI</pubmed_authors><pubmed_authors>Teixeira MR</pubmed_authors><pubmed_authors>Lu YJ</pubmed_authors><pubmed_authors>Rosenstein BS</pubmed_authors><pubmed_authors>Lophatananon A</pubmed_authors><pubmed_authors>Huynh-Le MP</pubmed_authors><pubmed_authors>Grindedal EM</pubmed_authors><pubmed_authors>Koutros S</pubmed_authors><pubmed_authors>Nordestgaard BG</pubmed_authors><pubmed_authors>UKGPCS collaborators</pubmed_authors><pubmed_authors>Andreassen OA</pubmed_authors><pubmed_authors>Muir KR</pubmed_authors><pubmed_authors>Pashayan N</pubmed_authors><pubmed_authors>Neal DE</pubmed_authors><pubmed_authors>Wiklund F</pubmed_authors><pubmed_authors>Petrovics G</pubmed_authors><pubmed_authors>Wolk A</pubmed_authors><pubmed_authors>Crawford DC</pubmed_authors><pubmed_authors>Kote-Jarai Z</pubmed_authors><pubmed_authors>MacInnis RJ</pubmed_authors><pubmed_authors>Eeles RA</pubmed_authors><pubmed_authors>Ingles SA</pubmed_authors><pubmed_authors>Martinez ME</pubmed_authors><pubmed_authors>NC-LA PCaP Investigators</pubmed_authors><pubmed_authors>Claessens F</pubmed_authors><pubmed_authors>Zheng W</pubmed_authors><pubmed_authors>Razack A</pubmed_authors><pubmed_authors>Stanford JL</pubmed_authors><pubmed_authors>Ost P</pubmed_authors><pubmed_authors>Nielsen SF</pubmed_authors><pubmed_authors>Mucci LA</pubmed_authors><pubmed_authors>Brenner H</pubmed_authors><pubmed_authors>Neuhausen SL</pubmed_authors><pubmed_authors>Travis RC</pubmed_authors><pubmed_authors>Blot WJ</pubmed_authors><pubmed_authors>Leach RJ</pubmed_authors><pubmed_authors>Mills IG</pubmed_authors><pubmed_authors>Hu JJ</pubmed_authors><pubmed_authors>Seibert TM</pubmed_authors><pubmed_authors>Cussenot O</pubmed_authors><pubmed_authors>Tangen CM</pubmed_authors><pubmed_authors>Kibel AS</pubmed_authors><pubmed_authors>Sorensen KD</pubmed_authors><pubmed_authors>van Schaik RHN</pubmed_authors><pubmed_authors>Vega A</pubmed_authors><pubmed_authors>Karunamuni R</pubmed_authors><pubmed_authors>Fan CC</pubmed_authors><pubmed_authors>Thompson WK</pubmed_authors><pubmed_authors>Park JY</pubmed_authors><pubmed_authors>Newcomb LF</pubmed_authors><pubmed_authors>West CML</pubmed_authors><pubmed_authors>Watya S</pubmed_authors><pubmed_authors>Profile Study Steering Committee</pubmed_authors><pubmed_authors>Haiman CA</pubmed_authors><pubmed_authors>John EM</pubmed_authors><pubmed_authors>Fowke JH</pubmed_authors><pubmed_authors>Schleutker J</pubmed_authors><pubmed_authors>Townsend PA</pubmed_authors><pubmed_authors>Logothetis CJ</pubmed_authors><pubmed_authors>Kogevinas M</pubmed_authors><pubmed_authors>Multigner L</pubmed_authors><pubmed_authors>Menegaux F</pubmed_authors><pubmed_authors>Gronberg H</pubmed_authors><pubmed_authors>De Ruyck K</pubmed_authors><pubmed_authors>Albanes D</pubmed_authors><pubmed_authors>IMPACT Study Steering Committee and Collaborators</pubmed_authors><pubmed_authors>Batra J</pubmed_authors><pubmed_authors>Maier C</pubmed_authors><pubmed_authors>Castelao JE</pubmed_authors><pubmed_authors>Dale AM</pubmed_authors><pubmed_authors>Parent ME</pubmed_authors><pubmed_authors>Hamilton RJ</pubmed_authors><pubmed_authors>Penney KL</pubmed_authors><pubmed_authors>Kaneva R</pubmed_authors><pubmed_authors>Canary PASS Investigators</pubmed_authors><pubmed_authors>Asona L</pubmed_authors><pubmed_authors>PRACTICAL Consortium</pubmed_authors><pubmed_authors>Cybulski C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.</name><description>&lt;h4>Background&lt;/h4>Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.&lt;h4>Methods&lt;/h4>In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-th</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-06-03T18:36:22.521Z</modification><creation>2026-04-30T03:11:17.056Z</creation></dates><accession>S-EPMC9372232</accession><cross_references><pubmed>35152271</pubmed><doi>10.1038/s41391-022-00497-7</doi></cross_references></HashMap>